Dachaigh › Melanoma › New York › New York City
Sgrùdaidhean clionaigeach Melanoma ann an New York City, NY
Tha 38 sgrùdaidhean airson Melanoma a’ lorg phàirtichean aig làraichean ann agus timcheall air New York City (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
A’ fastadhÌre 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A’ fastadhÌre 2
- Memorial Sloan Kettering Hospital, New York
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
A’ fastadhÌre 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
A’ fastadhÌre 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
A’ fastadh
- Weill Cornell Medicine, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
A’ fastadhÌre 2
- Local Institution - 0170, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
A’ fastadhÌre 1
- NYU Langone, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Hospital, New York
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
A’ fastadhÌre 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
A’ fastadh
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
A’ fastadhÌre 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Project: Every Child for Younger Patients With Cancer
A’ fastadhSgrùdadh amharc
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- agus 2 a bharrachd
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
A’ fastadhÌre 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
A’ fastadhÌre 2
- NYU Langone Health, New York
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
A’ fastadhÌre 1/2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
A’ fastadhÌre 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
A’ fastadhÌre 1/2
- Call for Information (Investigational Site 0031), New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
A’ fastadhÌre 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 2
- USA04-0, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A’ fastadhÌre 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Darovasertib in Primary Uveal Melanoma
A’ fastadhÌre 3
- Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center - 1275 York Ave, New York
- Northwell Health Cancer Institute, New York
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
A’ fastadhÌre 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- Memorial Slone Kettering Cancer Center, New York
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
A’ fastadhÌre 2/3
- Memorial Sloan Kettering Cancer Center, New York
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
A’ fastadhÌre 3
- Memorial Sloan Kettering Cancer Center, New York
ACTengine® IMA203 Combined With mRNA-4203
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center, New York
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
A’ fastadhÌre 2
- NYU Langone Health, New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, New York
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
A’ fastadh
- Memorial Sloan Kettering Cancer Center, New York
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Weill Cornell Medicine-New York-Presbyterian Hospital, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
A’ fastadhÌre 1/2
- NYU Langone Health, New York
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
A’ fastadh
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
A’ fastadhÌre 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Sgrùdaidhean Melanoma ann am bailtean eile
- Houston, TX59 sgrùdaidhean
- Los Angeles, CA34 sgrùdaidhean
- Nashville, TN33 sgrùdaidhean
- Pittsburgh, PA31 sgrùdaidhean
- Boston, MA26 sgrùdaidhean
- Philadelphia, PA23 sgrùdaidhean
- San Francisco, CA22 sgrùdaidhean
- Columbus, OH21 sgrùdaidhean
- Durham, NC21 sgrùdaidhean
- Atlanta, GA21 sgrùdaidhean
- Salt Lake City, UT21 sgrùdaidhean
- St. Louis, MO21 sgrùdaidhean
Sgrùdaidhean eile ann an New York City
- Aillse a' bhroilleach136 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag121 sgrùdaidhean
- Aillse (gach seòrsa)109 sgrùdaidhean
- Aillse Prostata103 sgrùdaidhean
- Ailse metastatach93 sgrùdaidhean
- Aillse colorectal78 sgrùdaidhean
- Cancer Ovarian69 sgrùdaidhean
- Ailseachadh nan Sgamhan60 sgrùdaidhean
- Myeloma iomaill60 sgrùdaidhean
- Cancer Pancreatic60 sgrùdaidhean
- Ailse Endometrial52 sgrùdaidhean
- Leukemia myeloid geur51 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.